Alkem Laboratories Ltd - 539523 - Closure of Trading Window
This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 29th September, 2022 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and half year ended 30th September, 2022 are communicated to the Stock Exchanges. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor meetings to be conducted. Why you should hold the stock of Alkem Laboratories
The stock at 3,258.8 is fairly valued Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor/ Broker Meeting to be conducted on 23rd September, 2022. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor/ Broker meetings to be conducted. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that US FDA had conducted a Pre-Approval inspection at the Company's manufacturing facility located at St. Louis, USA from 06th September, 2022 to 14th September, 2022. At the end of the inspection, the Company has received Form 483 with two (2) observations. There is no data integrity observation. This Pre-Approval Inspection is part of the routine business operations and the Company shall submit to US FDA within the stipulated timeline, a detailed response to close out the said observations. Alkem Laboratories Ltd - 539523 - Announcement Under Regulation 30 (LODR)- Cut-Off Date For Postal Ballot
This is to inform you that pursuant to the provisions of Section 110 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, the Board of Directors at its meeting held today i.e. 14th September, 2022 has decided to seek approval of the shareholders by way of postal ballot (voting by electronic means) for (a) appointment of Mr. Srinivas Singh (DIN: 06744441) as a Whole Time Director to be designated as an Executive Director for a period of five (5) consecutive years w.e.f 14th September, 2022 to 13th September, 2027 and (b) appointment of Mr. Sarandhar Singh- Vice President- Marketing and Sales to office/ place of profit in the Company. The Company has fixed 23rd September, 2022 as cut-off date for ascertaining the eligibility of shareholders for dispatch of Postal Ballot Notice and voting through electronic means. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Change in Directorate
We wish to inform you that the Board of Directors ('Board') of Alkem Laboratories Limited (the 'Company'), at its meeting held today, i.e. on 14th September, 2022 has appointed Mr. Srinivas Singh (DIN: 06744441) as an Additional Director and Whole Time Director designated as an Executive Director on the Board of Directors of the Company for a period of five (5) consecutive years, with effect from 14th September, 2022 upto 13th September, 2027, subject to the approval of the shareholders of the Company. Necessary particulars in relation to the said appointment, are included in Annexure I. We also confirm that Mr. Srinivas Singh is not debarred from holding office of director by virtue of any SEBI order or any other such authority. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor/ Broker meetings to be conducted. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor/ Broker meeting to be conducted on 07th September, 2022.